The primary purpose of this study is to measure and compare the amount of study drug in your blood after a single dose of two formulations of study drug.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
PF-07976016; formulation A - current/reference
PF-07976016; Formulation B - new/test
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, United States
Area Under the Curve - infinity - AUCinf (as data permit, otherwise AUClast).
Time frame: Day 1 Hour 0 (pre-dose) through 168 hours post dose in each period
Incidence of Treatment Emergent Adverse Events - TEAEs
Time frame: From first dose (Day 1) up to 28-35 days after final dose; a total of approximately 51 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.